Modern management of acute heart failure syndromes

European Heart Journal, Supplement

Volumn 7, Issue B, 2005, Pages

  Gheorghiade, Mihai ^a   Zannad, Faiez ^b,c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Ctr Hospitalier Univ de Nancy   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Acute disease; Congestive heart failure, classification pathophysiology mortality therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; INOTROPIC AGENT; MILRINONE; NESIRITIDE; NITRATE; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE HEART FAILURE SYNDROME; COMORBIDITY; CONGESTIVE HEART FAILURE; HEART ARRHYTHMIA; HEART MUSCLE INJURY; HUMAN; KIDNEY DISEASE; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYNDROME;

EID: 17144377866     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui006     Document Type: Review

References (41)

1. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, TX: American Heart Association; 2003.
2. Krumholz HM, Parent EM, Tu N et al. Readmission after hospitalisation for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997;157:99-104.
3. Klein L, Gheorghiade M. Therapeutic strategies for patients hospitalized with worsening heart failure. Ital Heart J 2003;4:71-74.
4. Zannad F, Cohen Solal A, Desnos M et al. Clinical and etiological features, management and outcomes of acute heart failure: the EFICA cohort study. Eur Heart J 2002;4(Suppl.):579.
5. Zannad F, Briancon S, Juilliere Yet al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. J Am Coll Cardiol 1999;33:734-742.
6. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463.
7. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(Suppl. 7):S21-S30.
8. McMurray J. Heart failure: we need more trials in typical patients. Eur Heart J 2000;21:699-700.
9. The ADHERE Registry. First Quarter 2004 National Benchmark Report. Fremont, CA: Scios Inc.; 2004.
10. Perna ER, Macin SM, Parras JI et al. Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 2002;143:814-820.
11. Stewart S, MacIntyre K, Hole DJ et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-322.
12. Opasich C, Rapezzi C, Lucci D et al. Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). Am J Cardiol 2001;88:382-387.
13. Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-1547.
14. Gheorghiade M, Gattis WA, O'Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971.
15. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-585.
16. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-391.
17. Colucci WS, Elkayam U, Horton DP et al: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253.
18. Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999;138:646-653.
19. Ishii J, Nomura M, Nakamura Y et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002;89:691-695.
20. Norwich TB, Patel J, MacLellan WR et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003;108:833-838.
21. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
22. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study); a randomised double-blind trial. Lancet 2002;360:196-202.
23. Kaluski E, Kobrin I, Zimlichman R et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003;41:204-210.
24. O'Connor CM, Gattis WA, Adams KF, Jr et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003;41:1452-1457.
25. Felker GM, Benza RL, Chandler AB et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003.
26. Torre-Amione G, Young JB, Colucci WS et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;42:140-147.
27. Francis GS, Siegel RM, Goldsmith SR et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
28. Northridge D. Frusemide or nitrates for acute heart failure? Lancet 1996;347:667-668.
29. Mehta RL, Pascual MT, Soroko S et al. Diuretics, mortality, and non-recovery of renal function in acute renal failure. JAMA 2002;288:2547-2553.
30. Emerman C, De Marco T, Costanzo MR et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. In 8th Annual Scientific Meeting of the Heart Failure Society of America; September 12-15 2004; Toronto, Canada.
31. Gheorghiade M, Hall V, Lakier JB et al. Comparative nemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989;13:134-142.
32. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
33. Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-1108.
34. Siostrzonek P, Koreny M, Delle-Karth G et al. Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiol Scand 2000;44:403-409.
35. Burger AJ, Elkayam U, Neibaur MT et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88:35-39.
36. Silver MA, Horton DP, Ghali JK et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798-803.
37. Gheorghiade M, Gattis WA, Klein L. OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization. Eur J Heart Fail 2003;5:9-12.
38. Slawsky MT, Colucci WS, Gottlieb SS et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-2227.
39. Gattis WA, O'Connor CM, Gallup DS et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43:1534-1541.
40. Komajda M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-474.
41. Nieminen MS, Akkila J, Hasenfuss G et al. Hemodynamic and neuro-humoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-1912.